Q1 Earnings Estimate for XENE Issued By HC Wainwright

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Xenon Pharmaceuticals in a report released on Wednesday, November 13th. HC Wainwright analyst D. Tsao forecasts that the biopharmaceutical company will earn ($0.88) per share for the quarter. HC Wainwright has a “Buy” rating and a $53.00 price target on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals’ Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.90) EPS and Q4 2025 earnings at ($0.91) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.01. During the same quarter in the prior year, the business earned ($0.73) EPS.

Several other brokerages also recently weighed in on XENE. Royal Bank of Canada reissued an “outperform” rating and set a $55.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday, September 3rd. William Blair raised Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Needham & Company LLC reissued a “buy” rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a report on Wednesday. Raymond James reissued an “outperform” rating and issued a $50.00 target price on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Finally, Wedbush reduced their price objective on shares of Xenon Pharmaceuticals from $50.00 to $49.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $57.45.

Xenon Pharmaceuticals Stock Performance

Xenon Pharmaceuticals stock opened at $39.83 on Friday. The stock has a market cap of $3.04 billion, a price-to-earnings ratio of -14.12 and a beta of 1.25. The stock’s 50 day simple moving average is $41.21 and its two-hundred day simple moving average is $40.34. Xenon Pharmaceuticals has a fifty-two week low of $28.10 and a fifty-two week high of $50.99.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC grew its position in shares of Xenon Pharmaceuticals by 2.2% during the 3rd quarter. FMR LLC now owns 6,917,684 shares of the biopharmaceutical company’s stock valued at $272,349,000 after acquiring an additional 149,511 shares during the period. Driehaus Capital Management LLC grew its position in shares of Xenon Pharmaceuticals by 2.3% in the second quarter. Driehaus Capital Management LLC now owns 4,419,472 shares of the biopharmaceutical company’s stock valued at $172,315,000 after purchasing an additional 97,732 shares during the period. Wellington Management Group LLP increased its stake in Xenon Pharmaceuticals by 0.4% during the 3rd quarter. Wellington Management Group LLP now owns 3,843,447 shares of the biopharmaceutical company’s stock worth $151,317,000 after buying an additional 15,226 shares in the last quarter. Braidwell LP increased its position in shares of Xenon Pharmaceuticals by 5.7% during the third quarter. Braidwell LP now owns 2,707,255 shares of the biopharmaceutical company’s stock worth $106,585,000 after purchasing an additional 146,682 shares in the last quarter. Finally, Janus Henderson Group PLC grew its stake in Xenon Pharmaceuticals by 144.2% during the 3rd quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock valued at $100,506,000 after acquiring an additional 1,507,135 shares in the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.